ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00247234
Recruitment Status : Completed
First Posted : November 1, 2005
Last Update Posted : September 25, 2017
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study intends to compare the effectiveness of schema therapy with standard psychiatric outpatient care for patients with borderline or avoidant personality disorder.

Condition or disease Intervention/treatment Phase
Personality Disorder, Borderline Avoidant Personality Disorder Behavioral: Schema Therapy Behavioral: standard care Not Applicable

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effectiveness of Group Based Schema Therapy in the Treatment of Borderline Personality Disorder and Avoidant Personality Disorder
Actual Study Start Date : September 2004
Actual Primary Completion Date : June 2011
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: schema therapy Behavioral: Schema Therapy
group based schema therapy
Active Comparator: standard care
standard psychiatric out-patient care
 Behavioral: standard care
standard psychiatric out-patient care


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. quality of life [ Time Frame: 5 years ]
    Self-report measures

  2. depression [ Time Frame: 5 years ]
    Self-report measures

  3. anxiety [ Time Frame: 5 years ]
    Self-report measures

  4. suicidal ideation [ Time Frame: 5 years ]
    Self-report measures


Secondary Outcome Measures :
  1. Use of psychotropic medication [ Time Frame: 5 years ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Avoidant or Borderline personality disorders

Exclusion Criteria:

  • Do not speak Scandinavian languages
  • Antisocial personality disorder
  • Narcissistic personality disorder
  • Affective bipolar disorder I
  • Schizophrenia
  • Mental impairment/organic brain disorder
  • Substance dependence
  • Planned pregnancy
  • Serious somatic illness
  • Anorexia Nervosa
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00247234


Locations
Norway
St. Olavs Hospital
Trondheim, Norway, 7030
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Study Chair: Are Holen, M.D., Ph.D. Department of Neuroscience, NTNU - Faculty of Medicine, MTFS, NO-7489 Trondheim, Norway
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00247234     History of Changes
Other Study ID Numbers: ursula.falkmer+AEA-stolav.no
First Posted: November 1, 2005    Key Record Dates
Last Update Posted: September 25, 2017
Last Verified: September 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Disease
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders